Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC)

NCT02499770 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

122

Enrollment

INDUSTRY

Sponsor class

Conditions

Small Cell Lung Cancer

Interventions

DRUG: Carboplatin
DRUG: Placebo
DRUG: Trilaciclib
DRUG: Etoposide

Sponsor

G1 Therapeutics, Inc.